We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Noninvasive Device Measures Hemoglobin More Accurately in Individuals with Darker Skin Pigmentations

By LabMedica International staff writers
Posted on 31 Oct 2022

Racial disparities in hemoglobin and blood oxygen measurements are an urgent public health issue. More...

The devices presently in use are inaccurate in people with dark skin. Most methods for monitoring hemoglobin require blood samples and expensive equipment. Currently available pulse-oximeters use red-infrared light and are based on technology first designed more than 50 years ago. The available noninvasive spectroscopic methods have a high degree of variability and often are inaccurate in people of color due to differences in skin melanin. There is a significant unmet need for a reliable, noninvasive device to estimate hemoglobin, irrespective of skin color. Now, researchers have demonstrated a new device that measures hemoglobin more accurately in individuals with darker skin pigmentations by using the spectroscopic properties of hemoglobin in the blue-green light spectra.

In a clinical study, a team of researchers at the University of Texas at Arlington (Arlington, TX, USA) along with Shani Biotechnologies LLC (Austin, TX, USA) measured the hemoglobin and oxygen content of 16 healthy volunteers using the newly developed technology. The team compared the results to those obtained using a commercially available pulse-oximeter for accuracy and variability. The findings of the study are encouraging, and the new technology has massive potential to address this clinical unmet need. The researchers intend to develop a wearable device, such as a watch or a monitor, that would read the blood through the skin.

“We have used the green-blue light and have successfully tested the device in preclinical and clinical studies,” said Dr. Vinoop Daggubati of Shani Biotechnologies LLC. “Our group has addressed the issues around shorter wavelength, scattering of light and the impact of skin melanin. The scientific community should open its mind to the concept of green light for these measurements. The Shani device has huge potential to eliminate this racial disparity.”

Related Links:
University of Texas at Arlington 
Shani Biotechnologies 


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.